Kari Vahervuo

This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Orion Corporation, Orion-Yhtyma Oy. Active years: 1990-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kari Vahervuo. Retrieved from https://idiyas.com/inventor/kari-vahervuo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 2.7

ph-index = 3

Forward Citations = 165(Granted Patents)

Company Filing History:

Years Active: 1990-2004

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6797732 - Pharmaceutical composition comprising entracapone, levodopa, and carbidopa (2004-09-28),

2. 6599530 - Oral compacted composition comprising catechol derivatives (2003-07-29),

3. 6500867 - Pharmaceutical composition comprising entacapone, levodopa, and carbidopa (2002-12-31),

4. 4935247 - Composition for the oral administration of pharmaceuticals (1990-06-19),

Title: The Innovative Contributions of Kari Vahervuo

Introduction

Kari Vahervuo is a notable inventor based in Espoo, Finland. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Parkinson's disease. With a total of 4 patents to his name, Vahervuo's work has had a meaningful impact on medical science.

Latest Patents

Vahervuo's latest patents include a pharmaceutical composition comprising entacapone, levodopa, and carbidopa. This oral solid fixed dose composition is designed to provide pharmacologically effective amounts of these compounds, which can be used for the treatment of Parkinson's disease. Another significant patent is an oral compacted composition comprising catechol derivatives. This invention focuses on the use of croscarmellose sodium to enhance the release rate of entacapone or nitecapone from the oral compacted composition.

Career Highlights

Throughout his career, Kari Vahervuo has worked with prominent companies in the pharmaceutical industry, including Orion Corporation and Orion-Yhtyma Oy. His expertise in drug formulation and development has been instrumental in advancing therapeutic options for patients.

Collaborations

Vahervuo has collaborated with several professionals in his field, including Matti Virkki and Marja Ritala. These partnerships have contributed to the successful development of his innovative pharmaceutical compositions.

Conclusion

Kari Vahervuo's contributions to pharmaceutical innovation demonstrate his commitment to improving treatment options for patients with Parkinson's disease. His patents reflect a deep understanding of drug formulation and a dedication to advancing medical science.

Profile summary based on public USPTO records.